A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients.

Drug Category : Array
Conference Category : Array
Lead Author : Changchun D, O'Connor O, et al.
Published Date : 02/06/2013
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASCO2013Poster8575.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top